Cargando…
Rituximab in the treatment of non-Hodgkin’s lymphoma
Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL). Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727901/ https://www.ncbi.nlm.nih.gov/pubmed/19707443 |
_version_ | 1782170706835931136 |
---|---|
author | Hauptrock, Beate Hess, Georg |
author_facet | Hauptrock, Beate Hess, Georg |
author_sort | Hauptrock, Beate |
collection | PubMed |
description | Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL). Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted worldwide as standard of care. Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 2 studies show a considerable efficiency for most of these B-NHL variants. Current research focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and combination with novel agents. |
format | Text |
id | pubmed-2727901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-27279012009-08-25 Rituximab in the treatment of non-Hodgkin’s lymphoma Hauptrock, Beate Hess, Georg Biologics Review Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL). Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted worldwide as standard of care. Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 2 studies show a considerable efficiency for most of these B-NHL variants. Current research focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and combination with novel agents. Dove Medical Press 2008-12 2008-12 /pmc/articles/PMC2727901/ /pubmed/19707443 Text en © 2008 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Hauptrock, Beate Hess, Georg Rituximab in the treatment of non-Hodgkin’s lymphoma |
title | Rituximab in the treatment of non-Hodgkin’s lymphoma |
title_full | Rituximab in the treatment of non-Hodgkin’s lymphoma |
title_fullStr | Rituximab in the treatment of non-Hodgkin’s lymphoma |
title_full_unstemmed | Rituximab in the treatment of non-Hodgkin’s lymphoma |
title_short | Rituximab in the treatment of non-Hodgkin’s lymphoma |
title_sort | rituximab in the treatment of non-hodgkin’s lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727901/ https://www.ncbi.nlm.nih.gov/pubmed/19707443 |
work_keys_str_mv | AT hauptrockbeate rituximabinthetreatmentofnonhodgkinslymphoma AT hessgeorg rituximabinthetreatmentofnonhodgkinslymphoma |